ECOR

Health Care Sector Update for 04/03/2020: ECOR, FATE, IMAB, JNJ, PFE, MRK, ABT, AMGN

Top Health Care Stocks:

JNJ: -0.16%

PFE: +0.30%

ABT: -0.26%

MRK: -0.48%

AMGN: -0.42%

Most health care giants were retreating pre-bell Friday.

Early movers include:

(+) electroCore (ECOR), which was surging by more than 83% after saying it has submitted an emergency use authorization (EUA) application to the US FDA to allow the study and use of its gammaCore Sapphire non-invasive vagus nerve stimulation therapy (nVNS), for respiratory symptoms associated with COVID-19.

(+) Fate Therapeutics (FATE) was gaining more than 16% in value amid a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ), to develop novel chimeric antigen receptor (CAR) NK and T-cell product candidates. Under the deal, the company will receive $50 million cash as well as a $50 million equity investment by Johnson & Johnson Innovation - JJDC Inc.

(+) I-Mab (IMAB) was advancing by more than 6% after saying the US FDA has cleared the company's investigational new-drug application (IND) to start clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with severe COVID-19.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.